AI could spot hidden lung danger in scleroderma patients

NCT ID NCT07236970

First seen Nov 19, 2025 · Last updated Jun 20, 2026 · Updated 35 times

Summary

This study is testing whether artificial intelligence (AI) can better detect a serious lung condition called pulmonary arterial hypertension (PAH) in people with scleroderma. Researchers will compare AI algorithms to traditional screening methods in 350 patients across multiple hospitals in Spain. The goal is to see if AI can catch PAH earlier and more accurately, which could lead to better outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, Madrid, 28041, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario Clínico San Cecilio

    RECRUITING

    Granada, Andalusia, 18007, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario Marqués de Valdecilla

    RECRUITING

    Santander, Cantabria, 39008, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario Ramón y Cajal

    RECRUITING

    Madrid, Madrid, 28034, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario Vall d'Hebron

    RECRUITING

    Barcelona, Catalonia, 08035, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

artificial intelligence algorithms

What this could lead to

If successful, this could lead to a more accurate, non-invasive screening method for early detection of pulmonary hypertension in scleroderma patients, potentially improving survival and quality of life.

What could go wrong

This is an observational study using existing data and AI models, not a treatment trial. The algorithms may not perform better than current methods, and results may not apply to all patient groups.

Conditions

The condition(s) this trial relates to.

pulmonary hypertension pulmonary systemic sclerosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.